Pharmacology Quiz: Ace Inhibitors And Arbs
20 questions · exam conditions
0:00
Ace Inhibitors And ArbsQuestion 1 of 20

An elderly patient with peripheral vascular disease and poorly controlled hypertension is initiated on candesartan. One week later, routine lab work reveals a serum creatinine increase from a baseline of 1.1 mg/dL to 2.5 mg/dL.

This acute decline in renal function is most likely due to the ARB-induced inhibition of angiotensin II-mediated constriction of the:

afferent arteriole.
efferent arteriole.
vasa recta.
proximal convoluted tubule.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Ace Inhibitors And Arbs

Practice Ace Inhibitors And Arbs in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Ace Inhibitors And Arbs, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

An elderly patient with peripheral vascular disease and poorly controlled hypertension is initiated on candesartan. One week later, routine lab work reveals a serum creatinine increase from a baseline of 1.1 mg/dL to 2.5 mg/dL.

This acute decline in renal function is most likely due to the ARB-induced inhibition of angiotensin II-mediated constriction of the:

  1. afferent arteriole.
  2. efferent arteriole. (correct answer)
  3. vasa recta.
  4. proximal convoluted tubule.
Explanation: In patients with hemodynamically significant renal artery stenosis (often suspected in patients with widespread atherosclerosis), glomerular filtration rate (GFR) is highly dependent on angiotensin II-mediated constriction of the efferent arteriole. This constriction increases hydrostatic pressure within the glomerulus, maintaining filtration. By blocking this effect, an ACE inhibitor or ARB causes efferent arteriole dilation, leading to a precipitous drop in intraglomerular pressure and GFR, which manifests as a sharp rise in serum creatinine.

Question 2

Captopril is an ACE inhibitor that differs from enalapril and lisinopril in that it has a shorter half-life requiring more frequent dosing. It also contains a specific chemical group that is thought to be responsible for a higher incidence of which adverse effects?

  1. Sulfhydryl group causing rash and taste disturbances. (correct answer)
  2. Carboxyl group causing more profound hyperkalemia.
  3. Phosphate group causing a higher risk of cough.
  4. Amine group causing a higher incidence of angioedema.
Explanation: Captopril contains a sulfhydryl (-SH) moiety, which is absent in most other commonly used ACE inhibitors (who are dicarboxylate-containing, like lisinopril, or phosphonate-containing, like fosinopril). This sulfhydryl group is associated with a higher incidence of specific side effects, including skin rash, taste disturbances (dysgeusia), and neutropenia, especially at higher doses. These side effects are less common with the non-sulfhydryl ACE inhibitors.

Question 3

A patient with HFrEF is on a stable regimen of sacubitril/valsartan, spironolactone, and dapagliflozin. He develops a complicated urinary tract infection and is prescribed a course of trimethoprim-sulfamethoxazole.

The addition of this antibiotic to his current regimen creates a significant and acute risk for which life-threatening adverse event?

  1. Severe hypoglycemia
  2. Bradykinin-mediated angioedema
  3. Life-threatening hyperkalemia (correct answer)
  4. Acute Fanconi syndrome
Explanation: This patient is on multiple drugs that increase serum potassium: valsartan (an ARB) and spironolactone (a mineralocorticoid receptor antagonist). Trimethoprim, a component of the antibiotic, is known to act like the potassium-sparing diuretic amiloride by blocking the epithelial sodium channel (ENaC) in the distal nephron. This action severely impairs potassium excretion. The combination of these three agents presents a very high risk of developing severe, potentially fatal hyperkalemia.

Question 4

A patient with type 2 diabetes and an eGFR of 25 mL/min/1.73m² is started on lisinopril for proteinuria. One week later, her serum creatinine rises from 2.4 mg/dL to 2.9 mg/dL (a ~21% increase). Which is the most appropriate interpretation and action?

  1. This indicates direct nephrotoxicity; the drug must be discontinued immediately.
  2. This rise suggests underlying bilateral renal artery stenosis; stop lisinopril and order a renal ultrasound.
  3. This is likely an allergic interstitial nephritis; a renal biopsy should be considered before stopping the drug.
  4. This is an expected hemodynamic effect; continue lisinopril with close monitoring of creatinine and potassium. (correct answer)
Explanation: Initiation of an ACE inhibitor or ARB often causes a small, self-limiting increase in serum creatinine (and decrease in eGFR) due to the beneficial reduction in intraglomerular pressure. A rise in creatinine of up to 30% from baseline is generally considered acceptable and is not a reason to stop the therapy, which provides long-term renal protection. The medication should be continued with ongoing monitoring. Discontinuation is only warranted for a rise >30%, progressive decline in renal function, or development of hyperkalemia.

Question 5

The therapeutic effects of ARBs are mediated by blocking the AT1 receptor. During ARB therapy, angiotensin II levels increase and can stimulate the unblocked AT2 receptor. What is the generally accepted physiological consequence of AT2 receptor stimulation?

  1. Increased aldosterone secretion and sodium retention, counteracting the drug's effect.
  2. Potent vasoconstriction and vascular smooth muscle proliferation.
  3. Vasodilation, anti-proliferative, and pro-apoptotic effects. (correct answer)
  4. Inhibition of renin release from the juxtaglomerular apparatus.
Explanation: The AT1 receptor mediates most of the well-known detrimental effects of angiotensin II (vasoconstriction, aldosterone release, proliferation). The AT2 receptor, which is highly expressed in fetal tissue and re-expressed in pathological states, is thought to counteract the effects of the AT1 receptor. Stimulation of the AT2 receptor is associated with beneficial effects such as vasodilation (via nitric oxide), anti-proliferation, and apoptosis, which may contribute to the overall therapeutic benefit of ARBs.

Question 6

A 55-year-old African American male presents to the emergency department with acute-onset swelling of his lips and tongue. His medical history is significant for hypertension, for which he was started on lisinopril 4 weeks ago.

This patient's clinical presentation is most likely mediated by the accumulation of which endogenous substance?

  1. Histamine
  2. Bradykinin (correct answer)
  3. Angiotensin II
  4. Leukotriene C4
Explanation: ACE inhibitor-induced angioedema is a non-allergic, non-histaminergic reaction caused by the inhibition of kininase II (which is the same enzyme as ACE). This leads to the accumulation of bradykinin, a potent vasodilator that increases vascular permeability, resulting in angioedema. This adverse effect is more common in patients of African American descent. Histamine mediates Type I hypersensitivity reactions, while leukotrienes are involved in other inflammatory pathways.

Question 7

A 68-year-old male is being discharged after an anterior wall myocardial infarction. His echocardiogram shows a left ventricular ejection fraction of 35%. His blood pressure is 110/70 mmHg and serum potassium is 4.2 mEq/L. The initiation of which medication is most critical for preventing adverse ventricular remodeling and reducing long-term mortality in this patient?

  1. Amlodipine
  2. Lisinopril (correct answer)
  3. Furosemide
  4. Clonidine
Explanation: In post-myocardial infarction patients with left ventricular systolic dysfunction (HFrEF), ACE inhibitors (or ARBs if ACEi-intolerant) are a cornerstone of therapy. They have been robustly shown to reduce mortality, decrease the risk of recurrent MI, and attenuate the process of adverse ventricular remodeling, where the ventricle dilates and changes shape, leading to progressive heart failure. Furosemide is for symptom control (congestion), while amlodipine and clonidine do not have this mortality benefit in post-MI HFrEF.

Question 8

A 60-year-old African American patient with newly diagnosed Stage 1 hypertension and no other comorbidities is being considered for antihypertensive monotherapy. According to major hypertension guidelines, which statement best describes the role of an ACE inhibitor as a first-line agent in this specific patient?

  1. It is a preferred first-line agent due to superior cardiovascular outcomes in this population.
  2. Its efficacy is equivalent to a beta-blocker, but it is preferred due to a better metabolic profile.
  3. It is contraindicated due to an unacceptably high risk of bradykinin-mediated adverse effects.
  4. It is generally less effective for blood pressure reduction compared to a thiazide diuretic or calcium channel blocker. (correct answer)
Explanation: When approaching hypertension treatment, you need to consider both patient demographics and guideline recommendations, as drug efficacy can vary significantly across different populations. The correct answer is D because major hypertension guidelines, including JNC 8 and AHA/ACC, specifically recognize that ACE inhibitors and ARBs tend to be less effective as monotherapy for blood pressure reduction in African American patients compared to thiazide diuretics or calcium channel blockers. This difference stems from the fact that African American patients more commonly have low-renin hypertension, making drugs that target the renin-angiotensin system less effective at lowering blood pressure. Choice A is incorrect because ACE inhibitors are not preferred first-line agents in African American patients - guidelines actually recommend thiazide diuretics or calcium channel blockers as preferred initial therapy. Choice B is wrong because beta-blockers are generally not recommended as first-line monotherapy for uncomplicated hypertension in any population due to inferior cardiovascular outcomes compared to other drug classes. Choice C overstates the risk - while ACE inhibitors can cause angioedema (which occurs more frequently in African Americans), the risk is not high enough to constitute a contraindication, and the primary issue here is efficacy, not safety. Study tip: Remember that hypertension treatment isn't one-size-fits-all. For pharmacology exams, know that African American patients typically respond better to thiazide diuretics and calcium channel blockers as first-line therapy, while ACE inhibitors/ARBs are more effective in Caucasian patients with high-renin hypertension.

Question 9

The primary therapeutic goal of using an ACE inhibitor in a normotensive patient with diabetic nephropathy is different from its goal in primary hypertension. Which of the following best describes this specific renal-protective mechanism?

  1. Preferential vasodilation of the efferent arteriole, reducing intraglomerular pressure. (correct answer)
  2. Increasing renal blood flow through significant vasodilation of the afferent arteriole.
  3. Improving glycemic control by directly increasing peripheral insulin sensitivity.
  4. Direct inhibition of glucose reabsorption in the proximal convoluted tubule.
Explanation: In diabetic nephropathy, hyperfiltration and increased intraglomerular pressure contribute to glomerular damage and proteinuria. Angiotensin II preferentially constricts the efferent arteriole. ACE inhibitors block angiotensin II production, leading to relatively more vasodilation of the efferent arteriole than the afferent arteriole. This reduces the hydrostatic pressure within the glomerulus, thereby decreasing proteinuria and slowing the progression of kidney disease, independent of the drug's effect on systemic blood pressure.

Question 10

A patient is initiated on lisinopril for hypertension. After four weeks of consistent therapy, which set of changes in circulating hormone and peptide levels is most likely to be observed as a direct and indirect consequence of the drug's mechanism?

  1. Decreased angiotensin II, decreased aldosterone, decreased renin, and decreased bradykinin.
  2. Decreased angiotensin II, decreased aldosterone, increased renin, and increased bradykinin. (correct answer)
  3. Increased angiotensin II, increased aldosterone, decreased renin, and increased bradykinin.
  4. Decreased angiotensin II, decreased aldosterone, increased renin, and decreased bradykinin.
Explanation: Lisinopril inhibits ACE, which prevents the conversion of angiotensin I to angiotensin II. This leads to decreased angiotensin II levels and, subsequently, decreased aldosterone secretion. The reduction in angiotensin II removes negative feedback on the juxtaglomerular cells, leading to an increase in renin release. ACE is also known as kininase II, an enzyme that degrades bradykinin. Therefore, ACE inhibition leads to an accumulation (increase) of bradykinin.

Question 11

A patient is initiated on lisinopril for hypertension. After four weeks of consistent therapy, which set of changes in circulating hormone and peptide levels is most likely to be observed as a direct and indirect consequence of the drug's mechanism?

  1. Decreased angiotensin II, decreased aldosterone, decreased renin, and decreased bradykinin.
  2. Decreased angiotensin II, decreased aldosterone, increased renin, and increased bradykinin. (correct answer)
  3. Increased angiotensin II, increased aldosterone, decreased renin, and increased bradykinin.
  4. Decreased angiotensin II, decreased aldosterone, increased renin, and decreased bradykinin.
Explanation: Lisinopril inhibits ACE, which prevents the conversion of angiotensin I to angiotensin II. This leads to decreased angiotensin II levels and, subsequently, decreased aldosterone secretion. The reduction in angiotensin II removes negative feedback on the juxtaglomerular cells, leading to an increase in renin release. ACE is also known as kininase II, an enzyme that degrades bradykinin. Therefore, ACE inhibition leads to an accumulation (increase) of bradykinin.

Question 12

A patient with heart failure is treated with a maximal dose of an ACE inhibitor. Despite initial improvement, plasma levels of angiotensin II return to near-baseline levels after several months of therapy. This phenomenon is partially attributed to angiotensin II production via ACE-independent pathways. Why might an angiotensin II receptor blocker (ARB) still provide clinical benefit in this patient?

  1. ARBs have a higher binding affinity for angiotensin II than ACE inhibitors.
  2. ARBs block the AT1 receptor, inhibiting the effects of angiotensin II regardless of its synthesis pathway. (correct answer)
  3. ARBs cause a more profound increase in bradykinin levels, leading to greater vasodilation.
  4. ARBs stimulate the production of angiotensin (1-7), which directly antagonizes ACE activity.
Explanation: The phenomenon described is often called 'ACE escape' or 'aldosterone escape'. Angiotensin II can be produced by alternative enzymes like chymase, particularly in cardiac tissue. An ACE inhibitor only blocks the ACE-mediated pathway. An ARB, however, works downstream by directly blocking the AT1 receptor. Therefore, it will inhibit the detrimental effects of angiotensin II whether it was produced by ACE or by an alternative pathway, making it potentially effective even when ACE inhibitor efficacy wanes.

Question 13

A 55-year-old African American male presents to the emergency department with acute-onset swelling of his lips and tongue. His medical history is significant for hypertension, for which he was started on lisinopril 4 weeks ago.

This patient's clinical presentation is most likely mediated by the accumulation of which endogenous substance?

  1. Histamine
  2. Bradykinin (correct answer)
  3. Angiotensin II
  4. Leukotriene C4
Explanation: ACE inhibitor-induced angioedema is a non-allergic, non-histaminergic reaction caused by the inhibition of kininase II (which is the same enzyme as ACE). This leads to the accumulation of bradykinin, a potent vasodilator that increases vascular permeability, resulting in angioedema. This adverse effect is more common in patients of African American descent. Histamine mediates Type I hypersensitivity reactions, while leukotrienes are involved in other inflammatory pathways.

Question 14

An elderly patient with peripheral vascular disease and poorly controlled hypertension is initiated on candesartan. One week later, routine lab work reveals a serum creatinine increase from a baseline of 1.1 mg/dL to 2.5 mg/dL.

This acute decline in renal function is most likely due to the ARB-induced inhibition of angiotensin II-mediated constriction of the:

  1. afferent arteriole.
  2. efferent arteriole. (correct answer)
  3. vasa recta.
  4. proximal convoluted tubule.
Explanation: In patients with hemodynamically significant renal artery stenosis (often suspected in patients with widespread atherosclerosis), glomerular filtration rate (GFR) is highly dependent on angiotensin II-mediated constriction of the efferent arteriole. This constriction increases hydrostatic pressure within the glomerulus, maintaining filtration. By blocking this effect, an ACE inhibitor or ARB causes efferent arteriole dilation, leading to a precipitous drop in intraglomerular pressure and GFR, which manifests as a sharp rise in serum creatinine.

Question 15

A 68-year-old male is being discharged after an anterior wall myocardial infarction. His echocardiogram shows a left ventricular ejection fraction of 35%. His blood pressure is 110/70 mmHg and serum potassium is 4.2 mEq/L. The initiation of which medication is most critical for preventing adverse ventricular remodeling and reducing long-term mortality in this patient?

  1. Amlodipine
  2. Lisinopril (correct answer)
  3. Furosemide
  4. Clonidine
Explanation: In post-myocardial infarction patients with left ventricular systolic dysfunction (HFrEF), ACE inhibitors (or ARBs if ACEi-intolerant) are a cornerstone of therapy. They have been robustly shown to reduce mortality, decrease the risk of recurrent MI, and attenuate the process of adverse ventricular remodeling, where the ventricle dilates and changes shape, leading to progressive heart failure. Furosemide is for symptom control (congestion), while amlodipine and clonidine do not have this mortality benefit in post-MI HFrEF.

Question 16

An 80-year-old female with HFrEF and chronic kidney disease (eGFR 40 mL/min/1.73m²) is being considered for ACE inhibitor therapy. Her current blood pressure is 105/65 mmHg and she has no signs of volume overload.

Which of the following represents the most appropriate and safe initiation strategy for RAAS inhibition in this patient?

  1. Start lisinopril at the standard dose of 10 mg daily to achieve rapid therapeutic benefit.
  2. Withhold ACE inhibitor therapy indefinitely due to the high risk of adverse effects.
  3. Administer an IV loading dose of enalaprilat to ensure adequate drug delivery.
  4. Start ramipril at a very low dose, such as 1.25 mg daily, and recheck labs in 1-2 weeks. (correct answer)
Explanation: When you encounter questions about ACE inhibitor initiation in elderly patients with comorbidities, focus on the balance between therapeutic benefit and safety considerations. This patient has multiple factors requiring cautious dosing: advanced age, kidney disease, and borderline low blood pressure. The correct approach is D - starting ramipril at 1.25 mg daily with close monitoring. In elderly patients with CKD, ACE inhibitors provide cardiovascular and renal protection in HFrEF, but must be initiated cautiously. The reduced kidney function (eGFR 40) means slower drug clearance, and the borderline BP (105/65) leaves little room for hypotension. Starting low allows you to assess tolerance while minimizing risks of hyperkalemia, acute kidney injury, or symptomatic hypotension. The 1-2 week recheck is essential to monitor creatinine, potassium, and blood pressure. A is dangerous because 10 mg is too high an initial dose for this patient's profile - it could cause severe hypotension or acute kidney injury. B is overly conservative; while this patient has risk factors, ACE inhibitors are still beneficial in HFrEF with CKD when used carefully. The key is cautious initiation, not avoidance. C makes no sense - IV enalaprilat is for hypertensive emergencies, not routine HFrEF management, and would be extremely dangerous given her low-normal BP. Study tip: For elderly patients with CKD starting RAAS inhibitors, remember "start low, go slow, and follow closely." Always consider baseline kidney function and BP when determining starting doses, and plan early follow-up for safety monitoring.

Question 17

A patient with HFrEF is on a stable regimen of sacubitril/valsartan, spironolactone, and dapagliflozin. He develops a complicated urinary tract infection and is prescribed a course of trimethoprim-sulfamethoxazole.

The addition of this antibiotic to his current regimen creates a significant and acute risk for which life-threatening adverse event?

  1. Severe hypoglycemia
  2. Bradykinin-mediated angioedema
  3. Life-threatening hyperkalemia (correct answer)
  4. Acute Fanconi syndrome
Explanation: This patient is on multiple drugs that increase serum potassium: valsartan (an ARB) and spironolactone (a mineralocorticoid receptor antagonist). Trimethoprim, a component of the antibiotic, is known to act like the potassium-sparing diuretic amiloride by blocking the epithelial sodium channel (ENaC) in the distal nephron. This action severely impairs potassium excretion. The combination of these three agents presents a very high risk of developing severe, potentially fatal hyperkalemia.

Question 18

A patient with type 2 diabetes and an eGFR of 25 mL/min/1.73m² is started on lisinopril for proteinuria. One week later, her serum creatinine rises from 2.4 mg/dL to 2.9 mg/dL (a ~21% increase). Which is the most appropriate interpretation and action?

  1. This indicates direct nephrotoxicity; the drug must be discontinued immediately.
  2. This rise suggests underlying bilateral renal artery stenosis; stop lisinopril and order a renal ultrasound.
  3. This is likely an allergic interstitial nephritis; a renal biopsy should be considered before stopping the drug.
  4. This is an expected hemodynamic effect; continue lisinopril with close monitoring of creatinine and potassium. (correct answer)
Explanation: Initiation of an ACE inhibitor or ARB often causes a small, self-limiting increase in serum creatinine (and decrease in eGFR) due to the beneficial reduction in intraglomerular pressure. A rise in creatinine of up to 30% from baseline is generally considered acceptable and is not a reason to stop the therapy, which provides long-term renal protection. The medication should be continued with ongoing monitoring. Discontinuation is only warranted for a rise >30%, progressive decline in renal function, or development of hyperkalemia.

Question 19

A patient with hypertension is taking hydrochlorothiazide. Lisinopril is added to their regimen. The addition of lisinopril can potentiate the antihypertensive effect of hydrochlorothiazide and also mitigate which of its common adverse metabolic effects?

  1. Hyperuricemia
  2. Hypercalcemia
  3. Hyperglycemia
  4. Hypokalemia (correct answer)
Explanation: When you encounter questions about drug combinations, focus on how different mechanisms can work synergistically while addressing each other's side effects. This question tests your understanding of thiazide diuretics and ACE inhibitors working together. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that lowers blood pressure by promoting sodium and water excretion. However, thiazides also cause potassium loss because they block sodium reabsorption in the distal convoluted tubule, leading to increased potassium secretion. This hypokalemia is one of HCTZ's most clinically significant adverse effects. Lisinopril, an ACE inhibitor, blocks the conversion of angiotensin I to angiotensin II. This reduces aldosterone production, which normally promotes potassium excretion. By decreasing aldosterone levels, lisinopril actually helps retain potassium, directly counteracting HCTZ's potassium-wasting effect. This makes D) hypokalemia the correct answer. Looking at the other options: A) Hyperuricemia occurs with thiazides because they compete with uric acid for excretion, but ACE inhibitors don't significantly affect uric acid levels. B) Hypercalcemia can occur with thiazides due to increased calcium reabsorption, but ACE inhibitors don't counteract this effect. C) Hyperglycemia is a thiazide side effect related to reduced insulin sensitivity, but ACE inhibitors have minimal impact on glucose metabolism. Remember this classic combination: thiazides waste potassium while ACE inhibitors spare it. This complementary relationship makes HCTZ + ACE inhibitor combinations extremely common in hypertension management, as they enhance efficacy while reducing the risk of dangerous electrolyte imbalances.

Question 20

Captopril is an ACE inhibitor that differs from enalapril and lisinopril in that it has a shorter half-life requiring more frequent dosing. It also contains a specific chemical group that is thought to be responsible for a higher incidence of which adverse effects?

  1. Sulfhydryl group causing rash and taste disturbances. (correct answer)
  2. Carboxyl group causing more profound hyperkalemia.
  3. Phosphate group causing a higher risk of cough.
  4. Amine group causing a higher incidence of angioedema.
Explanation: Captopril contains a sulfhydryl (-SH) moiety, which is absent in most other commonly used ACE inhibitors (who are dicarboxylate-containing, like lisinopril, or phosphonate-containing, like fosinopril). This sulfhydryl group is associated with a higher incidence of specific side effects, including skin rash, taste disturbances (dysgeusia), and neutropenia, especially at higher doses. These side effects are less common with the non-sulfhydryl ACE inhibitors.